DDInter462 DDInter1435
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Dabrafenib {u} (Compound) binds {v} (Gene) SLCO1B3
Dabrafenib {u} (Compound) upregulates {v} (Gene) PSAT1
Dabrafenib {u} (Compound) is included by {v} (Pharmacologic Class) Organic Anion Transporter 3 Inhibitors
Dabrafenib {u} (Compound) downregulates {v} (Gene) LIG1
Dabrafenib {u} (Compound) causes {v} (Side Effect) Abdominal pain
Dabrafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Dabrafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fostemsavir
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Dabrafenib {u} may lead to a major life threatening interaction when taken with {v} Levacetylmethadol
Dabrafenib (Compound) binds SLCO1B3 (Gene)
Dabrafenib (Compound) upregulates PSAT1 (Gene)
Dabrafenib (Compound) is included by Organic Anion Transporter 3 Inhibitors (Pharmacologic Class)
Dabrafenib (Compound) downregulates LIG1 (Gene)
Dabrafenib (Compound) causes Abdominal pain (Side Effect)
Dabrafenib may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Dabrafenib may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Dabrafenib may lead to a major life threatening interaction when taken with Levacetylmethadol